Natco Pharma is planning to relaunch the controversial nanotechnology-based breast cancer treatment Albupax in India following the Union health minister staying DCGI's order prohibiting the sale of the drug, reports said.

DP-b99, an experimental medicine to control neurological damages caused by stroke, may reach the market earlier than expected --in 3 to 4 years' time, reports said quoting D-Pharm's senior officials.

The Serum Institute of India (SII), India's largest vaccine maker, has announced the commencement of the last crucial phases of human trials of its swine flu vaccine Fluvac.

Fruitflow, a tomato-extract product developed by Provexis, has been found effective to prevent blood clots that risk heart attacka nd strokes without the side-effects of the widely used blood thinner Aspirin.

Hizentra, a 20 percent concentration of human immunoglobulin to be administered subcutaneously for treating patients diagnosed with primary immunodeficiency (PI), has been granted approval in US.